Ho Min-Chieh, Hsieh Yi-Ting, Shen Elizabeth P, Hsu Wei-Cherng, Cheng Han-Chih
Department of Ophthalmology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Hualien, Taiwan.
School of Medicine, Tzu Chi University, Hualien, Taiwan.
Taiwan J Ophthalmol. 2019 Feb 20;10(2):111-115. doi: 10.4103/tjo.tjo_110_18. eCollection 2020 Apr-Jun.
The purpose of this study is to explore short-term refractive and ocular parameter changes and their correlations after cycloplegia with atropine.
This is a prospective clinical trial that enrolled 96 eyes of 96 participants (mean age, 8.5 ± 2.1 years). Spherical equivalent refractive error (SER), axial length (AL), mean keratometric value (mean-K), anterior chamber depth (ACD), and intraocular pressure (IOP) were measured at baseline and 1 week after topical use of 0.125% atropine. Postcycloplegic changes of refractive error and ocular parameters were evaluated, and their correlations were analyzed with multiple linear regression models.
After topical atropine use, the mean AL decreased by 0.016 mm ( = 0.008), and the mean ACD increased by 0.58 mm ( < 0.0001). There was no significant change in the Mean-K or IOP. Eighty-two eyes (85%) had an emmetropic or hyperopic shift, and 14 (15%) had a myopic shift. Those with an emmetropic or hyperopic shift had their mean AL shortened by 0.023 mm, whereas the eyes with myopic shifts had their mean AL lengthened by 0.026 mm ( = 0.003). Change in SER was negatively correlated with change in AL (-2.57 D for an increase of 1 mm in AL, < 0.001) and positively correlated with change in ACD (+0.96 D for an increase of 1 mm in ACD, = 0.013).
Most eyes had emmetropic or hyperopic changes after short-term topical atropine use, and AL shortening and anterior chamber deepening both contributed to the hyperopic changes. Meanwhile, myopic change may be observed in some eyes (15%), which were related to transient AL elongation but not invalid myopic control. This encouraged clinicians to sustain the atropine treatment for a longer period before switching to other modalities for myopic control in clinical practice.The clinical trial registration number NCT03839888 (clinicaltrials.gov).
本研究旨在探讨阿托品睫状肌麻痹后短期屈光及眼部参数变化及其相关性。
这是一项前瞻性临床试验,纳入了96名参与者的96只眼(平均年龄8.5±2.1岁)。在基线时以及局部使用0.125%阿托品1周后测量等效球镜度屈光不正(SER)、眼轴长度(AL)、平均角膜曲率值(平均-K)、前房深度(ACD)和眼压(IOP)。评估睫状肌麻痹后屈光不正和眼部参数的变化,并使用多元线性回归模型分析它们的相关性。
局部使用阿托品后,平均AL缩短了0.016mm(P = 0.008),平均ACD增加了0.58mm(P < 0.0001)。平均-K或IOP无显著变化。82只眼(85%)出现正视或远视偏移,14只眼(15%)出现近视偏移。出现正视或远视偏移的眼平均AL缩短了0.023mm,而出现近视偏移的眼平均AL延长了0.026mm(P = 0.003)。SER的变化与AL的变化呈负相关(AL每增加1mm,SER降低-2.57D,P < 0.001),与ACD的变化呈正相关(ACD每增加1mm,SER增加+0.96D,P = 0.013)。
短期局部使用阿托品后,大多数眼出现正视或远视变化,AL缩短和前房加深均导致远视变化。同时,部分眼(15%)可能出现近视变化,这与短暂的AL延长有关,但并非近视控制无效。这鼓励临床医生在临床实践中,在改用其他近视控制方法之前,持续使用阿托品治疗更长时间。临床试验注册号NCT03839888(clinicaltrials.gov)。